Medicine and Dentistry
Absorbed Dose
47%
Albumin
9%
Biodistribution
13%
Bone Marrow
8%
Cells
20%
Combination Therapy
67%
DNA Damage
19%
Dosimetry
61%
Enalapril Maleate
10%
Evaluation Study
34%
Gallium 68
9%
Gastrin Releasing Peptide Receptor
12%
Hormone
15%
Indium 111
8%
Injection
17%
Inpatient
11%
Kidney
38%
Lesion
14%
Ligand
22%
Liver
17%
Lutetium 177
100%
Magnetic Resonance Imaging
8%
Man
13%
Microsphere
13%
Neoplasm
40%
Nephrotoxicity
10%
Neuroendocrine Tumor
30%
Nuclear Medicine
16%
Organ
26%
Patient
54%
Peptide
11%
Peptide Receptor
28%
PET-CT
8%
Position
17%
Prostate Cancer
35%
Radiation Biology
10%
Radioactive Tracer
9%
Radioembolization
13%
Radioisotope
11%
Radioligand
12%
Radionuclide Therapy
65%
Radiopharmaceutical Agent
13%
Somatostatin Receptor
16%
Survival
16%
Tetraxetan
23%
Therapeutic Procedure
82%
Toxicity
21%
Treatment Response
8%
Xenograft
9%
Yttrium 90
11%
Pharmacology, Toxicology and Pharmaceutical Science
Actinium 225
8%
Adverse Event
5%
Animal
7%
Base
5%
Biodistribution
11%
Biological Marker
6%
Biological Product
14%
Cancer Model
6%
Cholecystokinin B Receptor
6%
Diseases
5%
DNA
19%
Dosimetry
45%
Enalapril Maleate
11%
Fluorodeoxyglucose F 18
6%
Gallium 68
8%
Gastrin Releasing Peptide Receptor
12%
Indium 111
8%
Ligand
25%
Liver Cancer
6%
Liver Cell Carcinoma
6%
Liver Metastasis
6%
Lutetium 177
92%
Meningioma
6%
Metastasis
11%
Microsphere
13%
Mouse
15%
Neoplasm
40%
Neuroendocrine Tumor
24%
Peptide
11%
Pharmacokinetics
7%
Preclinical Study
8%
Prostate Cancer
32%
Prostate Specific Membrane Antigen
22%
Radioisotope
68%
Radioligand
25%
Radiopharmaceutical Agent
17%
Receptor
29%
Receptor Antagonist
6%
Receptor Subtype
5%
Somatostatin Receptor
16%
Somatostatin Receptor 2
6%
Survival
17%
Technetium 99m
6%
Tenidap
5%
Tetraxetan
8%
Thyroid Cancer
6%
Toxicity
15%
Tracer
10%
Yttrium 90
15%
Zirconium 89
6%
Nursing and Health Professions
Absorbed Dose
20%
Combination Therapy
36%
Consensus
6%
DNA
6%
Dose
9%
Dosimetry
35%
Enalapril Maleate
6%
Evaluation Study
10%
Holmium
6%
Hormone
7%
Liver Tumor
6%
Lutetium 177
23%
Measurement
7%
Neoplasm
9%
Nuclear Magnetic Resonance Imaging
6%
Patient
10%
Prescription
5%
Procedures
7%
Prostate Cancer
9%
Radioembolization
13%
Radioisotope
6%
Receptor
6%
Sample
5%
Standard
16%
Survival
6%
Technetium-99m
6%
Time
8%
Treatment Outcome
6%
Volume
9%
Yttrium 90
6%